Cellivery "Received Proposal for Joint Development of Parkinson's Disease Treatment from Wistar Institute under US NCI"

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 8th that its iCP-Parkin, which is being developed as a treatment for degenerative brain diseases, has received a proposal for expanding the indication of iCP-Parkin as an anti-cancer drug and for joint research from the Wistar Institute under the U.S. National Cancer Institute (NCI).

The Wistar Institute is an independent new drug research and development institute designated by the U.S. National Cancer Institute in the biomedical field. Focusing on vaccine and anti-cancer agent development, it conducts new drug research and development with 31 laboratories, 58 PhD-level researchers, and 289 staff members. It is currently operated with federal funding as part of the U.S. National Cancer Institute.

Cellivery’s self-developed iCP-Parkin is a treatment for degenerative brain diseases utilizing the TSDT platform technology, a pharmacological substance in vivo delivery technology, and has shown efficacy in recovering motor and cognitive functions in Parkinson’s and Alzheimer’s diseases.

It is globally recognized as a next-generation treatment for degenerative brain diseases capable of freely crossing the blood-brain barrier. It was also published in the journal Science Advances that iCP-Parkin effectively prevents the accumulation of alpha-synuclein aggregates, proteins that cause Parkinson’s disease, demonstrating excellent therapeutic efficacy for Parkinson’s disease.

Cellivery plans to use this opportunity as a stepping stone to advance joint development and sequential licensing for expanding indications to anti-cancer drugs through aggressive discussions with global big pharma.

Currently, Cellivery is negotiating to complete joint development discussions with the Wistar Institute within this month and aims to finalize the contract by December.

This content was produced with the assistance of AI translation services.